Popular Filters
Trials for MTC Patients
Bi-specific T-Cell Engager
Tarlatamab + Radiation for Cancer
Recruiting1 awardPhase 1 & 2
Tucson, Arizona
This trial is looking at the safety of adding a drug called tarlatamab to standard radiation therapy for patients with cancer. The study will first include 20-24 patients with cancer outside the brain
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Trials for Metastatic Patients
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
Recruiting1 awardPhase 2
Ann Arbor, Michigan
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Trials With No Placebo
Bi-specific T-Cell Engager
Tarlatamab + Radiation for Cancer
Recruiting1 awardPhase 1 & 2
Tucson, Arizona
This trial is looking at the safety of adding a drug called tarlatamab to standard radiation therapy for patients with cancer. The study will first include 20-24 patients with cancer outside the brain
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
Recruiting1 awardPhase 1 & 2
Scottsdale, Arizona
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.